BRD4 and neoplasm: For example, the BRD4 inhibitor JQ1, in which BRD4 is a member of the BET family (Bromodomain and Extra Terminal domain), has shown therapeutic potential in patient-derived xenografts by impairing tumour progression and sensitizing tumours to PARP inhibitors [13,14].